vs
Side-by-side financial comparison of Evaxion A/S (EVAX) and Hafnia Ltd (HAFN). Click either name above to swap in a different company.
Evaxion A/S is the larger business by last-quarter revenue ($37.0K vs $31.0K, roughly 1.2× Hafnia Ltd).
Evaxion A/S is a Danish clinical-stage biotechnology company that leverages proprietary artificial intelligence platforms to develop targeted immunotherapies. Its core pipeline includes personalized cancer vaccines, off-the-shelf immuno-oncology treatments, and novel infectious disease therapies, advancing programs through partnerships with global pharmaceutical stakeholders.
Hafnia Ltd is a leading global shipping firm focused on operating product and chemical tanker fleets. It transports diverse bulk liquid cargoes including refined petroleum products, specialty chemicals, and edible oils, catering to clients across the energy, chemical manufacturing, and agricultural commodity industries worldwide.
EVAX vs HAFN — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2024
| Metric | | |
|---|---|---|
| Revenue | $37.0K | $31.0K |
| Net Profit | $-4.8M | — |
| Gross Margin | — | — |
| Operating Margin | -11729.7% | — |
| Net Margin | -13056.8% | — |
| Revenue YoY | -76.0% | — |
| Net Profit YoY | 22.1% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $37.0K | — | ||
| Q2 24 | $154.0K | — | ||
| Q1 24 | — | $31.0K | ||
| Q2 23 | $0 | — |
| Q2 25 | $-4.8M | — | ||
| Q2 24 | $-6.2M | — | ||
| Q1 24 | — | — | ||
| Q2 23 | $-5.7M | — |
| Q2 25 | -11729.7% | — | ||
| Q2 24 | -2974.7% | — | ||
| Q1 24 | — | — | ||
| Q2 23 | — | — |
| Q2 25 | -13056.8% | — | ||
| Q2 24 | -4024.7% | — | ||
| Q1 24 | — | — | ||
| Q2 23 | — | — |
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q2 23 | $-0.21 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | — |
| Total DebtLower is stronger | $9.2M | — |
| Stockholders' EquityBook value | $6.2M | — |
| Total Assets | $22.4M | — |
| Debt / EquityLower = less leverage | 1.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $14.7M | — | ||
| Q2 24 | $8.0M | — | ||
| Q1 24 | — | — | ||
| Q2 23 | $7.1M | — |
| Q2 25 | $9.2M | — | ||
| Q2 24 | $8.4M | — | ||
| Q1 24 | — | — | ||
| Q2 23 | $8.2M | — |
| Q2 25 | $6.2M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | — | — | ||
| Q2 23 | $2.5M | — |
| Q2 25 | $22.4M | — | ||
| Q2 24 | $15.2M | — | ||
| Q1 24 | — | — | ||
| Q2 23 | $16.8M | — |
| Q2 25 | 1.48× | — | ||
| Q2 24 | 6.72× | — | ||
| Q1 24 | — | — | ||
| Q2 23 | 3.25× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
